Relieves nasal and non-nasal symptoms. ANDA 78352, held by Lupin Pharms. Desloratadine.
As of Nov 16, 2026, ANDA 78352 (Desloratadine), held by Lupin Pharms, was first approved by FDA on Oct 25, 2010, with 2 approved supplements and 0 published complete response letters.
Desloratadine tablets are histamine-1 (H1) receptor antagonist indicated for: Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 12 years of age and older. Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 12 years of age and older. 1.1 Seasonal Allergic Rhinitis Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. 1.2 Perennial Allergic Rhinitis Desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 25, 2010 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desloratadine5MG · tablet;oral | Desloratadine | Rx |
| Oct 22, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 22, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Oct 25, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters